Pembrolizumab (KEYTRUDA®) Clinical Trials
8 recruitingDrug
Phase 27Phase 15Phase 32
Showing 1–8 of 8 trials
Recruiting
Phase 2Phase 3
FORTIFI-HN01: A Study of Ficerafusp Alfa (BCA101) or Placebo in Combination With Pembrolizumab in First-Line PD-L1-pos, R or M HNSCC
Metastatic Head and Neck Squamous Cell CarcinomaRecurrent Head and Neck Squamous Cell Carcinoma
Bicara Therapeutics650 enrolled173 locationsNCT06788990
Recruiting
Phase 2Phase 3
A Safety and Efficacy Study of EIK1001 in Combination With Pembrolizumab and Chemotherapy in Participants With Stage 4 Non-Small Cell Lung Cancer.
Stage 4 NSCLCNon Small Cell Lung Cancer (Squamous or Non Squamous)
Eikon Therapeutics750 enrolled3 locationsNCT07365319
Recruiting
Phase 1Phase 2
GI-101/GI-101A as a Single Agent or in Combination With Pembrolizumab or Lenvatinib in Advanced Solid Tumors
Cervical CancerUrothelial CarcinomaAdvanced Solid Tumor+3 more
GI Innovation, Inc.317 enrolled12 locationsNCT04977453
Recruiting
Phase 2
Neoadjuvant, SBRT With Intratumoural Pembrolizumab Followed by Neoadjuvant Chemotherapy in Breast Cancer
Breast CancerBreast Cancer Stage IIBreast Cancer Invasive+2 more
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's40 enrolled2 locationsNCT07188246
Recruiting
Phase 1
Intratumoral Delivery of Viral Replicon (saRNA) Particles Expressing IL-12 in Head and Neck Cancer
Head and Neck CancerSolid TumorsHNSCC+10 more
VLP Therapeutics41 enrolled1 locationNCT06736379
Recruiting
Phase 1Phase 2
ADG126 in Combination With Pembrolizumab in Patients With Advanced/Metastatic Solid Tumors
Advanced/Metastatic Solid Tumors
Adagene Inc186 enrolled21 locationsNCT05405595
Recruiting
Phase 1Phase 2
A Study Assessing KB707 for the Treatment of Advanced Solid Tumor Malignancies Affecting the Lungs
Advanced CancerLung Cancer (Non-Small Cell)Solid Tumor, Adult+2 more
Krystal Biotech, Inc.250 enrolled14 locationsNCT06228326
Recruiting
Phase 1Phase 2
A Beta-only IL-2 ImmunoTherapY Study
Triple-Negative Breast CancerEsophageal CancerGastric Cancer+34 more
Medicenna Therapeutics, Inc.115 enrolled27 locationsNCT05086692